Richard Wheelhouse

Dr. Richard Wheelhouse


Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 1997 in Cancer Treatment Reviews
Verified
Journal Article
Closed access
ENE.S. Newlands
E.S. Newlands
MSM.F.G. Stevens
M.F.G. Stevens
SWS.R. Wedge
S.R. Wedge
RWRichard Wheelhouse
Richard Wheelhouse
CBC. Brock
C. Brock

20 March 1998 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
RWRichard Wheelhouse
Richard Wheelhouse
DSDaekyu Sun
Daekyu Sun
HHHaiyong Han
Haiyong Han
FHFrank Xiaoguang Han
Frank Xiaoguang Han
LHLaurence H. Hurley
Laurence H. Hurley

1 August 1994 in Biochemistry
Verified
Journal Article
Closed access
BDBrian J. Denny
Brian J. Denny
RWRichard Wheelhouse
Richard Wheelhouse
MSMalcolm F. G. Stevens
Malcolm F. G. Stevens
LTLincoln L. H. Tsang
Lincoln L. H. Tsang
JSJohn A. Slack
John A. Slack

1 April 1999 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
FHFrank Xiaoguang Han
Frank Xiaoguang Han
RWRichard Wheelhouse
Richard Wheelhouse
LHLaurence H. Hurley
Laurence H. Hurley

27 November 2001 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
DSDong-Fang Shi
Dong-Fang Shi
RWRichard Wheelhouse
Richard Wheelhouse
DSDaekyu Sun
Daekyu Sun
LHLaurence H. Hurley
Laurence H. Hurley

25 November 2013 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
YRYulian P. Ramirez
Yulian P. Ramirez
JWJessica L. Weatherbee
Jessica L. Weatherbee
RWRichard Wheelhouse
Richard Wheelhouse
ARAlonzo Ross
Alonzo Ross
Glioblastoma multiforme (GBM) is a grade IV brain tumor characterized by a heterogeneous population of cells that are highly infiltrative, angiogenic and resistant to chemotherapy. The current standard of care, comprised of surgical resection followed by radiation and the chemotherapeutic agent temozolomide, only provides patients with a 12–14 month survival period post-diagnosis. Long-term survival for GBM patients remains uncommon as cells with intrinsic or acquired resistance to treatment repopulate the tumor. In this review we will describe the mechanisms of resistance, and how they may be overcome to improve the survival of GBM patients by implementing novel chemotherapy drugs, new drug combinations and new approaches relating to DNA damage, angiogenesis and autophagy.